Lucia Y. Chen

Luton, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications

Breast and axillary nodal amyloidosis in breast screening clinic.

Breast and axillary nodal amyloidosis in breast screening clinic.

Journal: BMJ case reports
Published: August 04, 2025

Outcomes of radiologically diagnosed solitary fibrous tumours of the pleura.

Outcomes of radiologically diagnosed solitary fibrous tumours of the pleura.

Journal: ERJ open research
Published: July 29, 2025

Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies.

Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies.

Journal: Blood
Published: July 21, 2025

Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies.

Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies.

Journal: Blood
Published: July 21, 2025

Mezigdomide reverses T-cell exhaustion through degradation of IKZF1/IKZF3 and reinvigoration of cytokine production pathways.

Mezigdomide reverses T-cell exhaustion through degradation of IKZF1/IKZF3 and reinvigoration of cytokine production pathways.

Journal: Blood
Published: July 18, 2025

Mezigdomide reverses T-cell exhaustion through degradation of IKZF1/IKZF3 and reinvigoration of cytokine production pathways.

Mezigdomide reverses T-cell exhaustion through degradation of IKZF1/IKZF3 and reinvigoration of cytokine production pathways.

Journal: Blood
Published: July 18, 2025

MRD-negative duration following latest line of therapy predicts long-term PFS in real-world patients with multiple myeloma.

MRD-negative duration following latest line of therapy predicts long-term PFS in real-world patients with multiple myeloma.

Journal: Blood advances
Published: June 28, 2024

Supportive care measures for bispecific T-cell engager therapies in haematological malignancies.

Supportive care measures for bispecific T-cell engager therapies in haematological malignancies.

Journal: Current opinion in supportive and palliative care
Published: April 23, 2024

Longitudinal dynamics and clinically available predictors of poor response to COVID-19 vaccination in multiple myeloma.

Longitudinal dynamics and clinically available predictors of poor response to COVID-19 vaccination in multiple myeloma.

Journal: Haematologica
Published: September 17, 2023

Cellular mechanisms associated with sub-optimal immune responses to SARS-CoV-2 bivalent booster vaccination in patients with Multiple Myeloma.

Cellular mechanisms associated with sub-optimal immune responses to SARS-CoV-2 bivalent booster vaccination in patients with Multiple Myeloma.

Journal: EBioMedicine
Published: August 23, 2023

Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myeloma.

Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myeloma.

Journal: Frontiers in oncology
Published: September 06, 2022

Venetoclax induces deep and durable minimal residual disease-negative remission in high-risk TP53 disrupted B prolymphocytic leukaemia.

Venetoclax induces deep and durable minimal residual disease-negative remission in high-risk TP53 disrupted B prolymphocytic leukaemia.

Journal: European journal of haematology
Published: April 23, 2022
Showing 1-12 of 27

Last Updated: 09/26/2026